Avanir Pharmaceuticals, Inc.
) recently entered into a settlement agreement with Wockhardt to
resolve their patent litigation regarding Nuedexta. Wockhardt had
filed an abbreviated new drug application (ANDA) to get its
generic version of Avanir's Nuedexta approved.
However, with the litigation being settled, Wockhardt can now
sell its generic version of Nuedexta on Jul 30, 2026 or before
under certain circumstances. Avanir and Wockhardt have also filed
for the dismissal of the patent litigation.
We remind investors that in Aug 2013 and earlier this month,
Avanir settled its Nuedexta patent litigation with
) generic arm Sandoz and
) respectively. Meanwhile, two other companies,
Impax Laboratories, Inc.
) and Par Pharmaceutical Companies, Inc., have also filed ANDAs
for their generic versions of Nuedexta. Litigation against these
ANDA filers is in progress.
We note that Nuedexta was launched in the U.S. in Jan 2011 for
the treatment of pseudobulbar affect (PBA). Net Nuedexta revenues
grew 15.2% sequentially to $19 million in the third quarter of
fiscal 2013 ended Jun 30.
In Jun 2013, Avanir received approval for Nuedexta in the EU
for the treatment of patients suffering from PBA. The marketing
application was based on comprehensive data from phase III
studies of Nuedexta in patients with PBA, plus data from
longer-term safety studies.
Avanir expects to report top-line data from the PRIME study in
the fourth quarter of calendar 2013. This study is being
conducted to evaluate the efficacy of Nuedexta for the treatment
of central neuropathic pain in multiple sclerosis.
This drug is being studied for two additional indications,
namely, agitation in Alzheimer's disease (phase II) and
levodopa-induced-dyskinesia in Parkinson's disease (phase
Avanir currently carries a Zacks Rank #3 (Hold). Currently,
Actavis looks better positioned with a Zacks Rank #2 (Buy).
ACTAVIS INC (ACT): Free Stock Analysis Report
AVANIR PHARM (AVNR): Free Stock Analysis
IMPAX LABORATRS (IPXL): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
To read this article on Zacks.com click here.